Global Blood Therapeutics found using ticker (GBT) have now 19 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The target price ranges between 102 and 31 and has a mean target at 59.53. Now with the previous closing price of 32.4 this would imply there is a potential upside of 83.7%. The 50 day moving average now sits at 29.73 while the 200 day moving average is 30.56. The market capitalisation for the company is $2,144m. Find out more information at: https://www.gbt.com
The potential market cap would be $3,939m based on the market concensus.
Global Blood Therapeutics, a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A. to two early-stage research programs in SCD. Global Blood Therapeutics was incorporated in 2011 and is headquartered in South San Francisco, California.
